Showing results (1-10 of 76) with videos related to
Sort By:
Pageof 8
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde|June 7, 2012
The complexity of HIV vasculopathyAlan Stanley, Sally Candy, Candyce Levin, et al.Journal of the Neurological Sciences|September 3, 2022
A single low-dose rituximab infusion in severe chronic refractory myasthenia gravis in resource-limited settingsJeannine M HeckmannAnnals of the New York Academy of Sciences|October 7, 2017
A unique subphenotype of myasthenia gravisJeannine M Heckmann, Melissa NelFrontiers in Neurology|September 25, 2020
Management Issues in Myasthenia Gravis Patients Living With HIV: A Case Series and Literature ReviewJeannine M Heckmann, Suzaan MaraisOrphanet Journal of Rare Diseases|January 31, 2019
Profiling of patient-specific myocytes identifies altered gene expression in the ophthalmoplegic subphenotype of myasthenia gravisMelissa Nel, Sharon Prince, Jeannine M HeckmannJournal of the Neurological Sciences|May 8, 2009
Opsoclonus-myoclonus syndrome and HIV-infectionKirsten M Scott, Faheema Parker, Jeannine M HeckmannOrphanet Journal of Rare Diseases|December 14, 2020
Gene expression profiling of orbital muscles in treatment-resistant ophthalmoplegic myasthenia gravisTarin A Europa, Melissa Nel, Jeannine M HeckmannNeuromuscular Disorders : NMD|April 29, 2019
A review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular musclesTarin A Europa, Melissa Nel, Jeannine M HeckmannMuscle & Nerve|May 24, 2018
Myasthenic ophthalmoparesis: Time To resolution after initiating immune therapiesTarin A Europa, Melissa Nel, Jeannine M HeckmannNeuromuscular Disorders : NMD|April 8, 2014
The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: implications in myasthenia gravisJennifer Auret, Amaal Abrahams, Sharon Prince, et al.Pageof 8